



Age/Gender : 29 Y 7 M 19 D/M UHID/MR No : SCHI.0000016658

Visit ID : SCHIOPV23778

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : SDGfdg Collected : 09/Dec/2023 10:18AM

Received : 09/Dec/2023 11:00AM Reported : 09/Dec/2023 03:01PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - TMT - PAN INDIA - FY2324

PERIPHERAL SMEAR , WHOLE BLOOD EDTA





 Age/Gender
 : 29 Y 7 M 19 D/M

 UHID/MR No
 : SCHI.0000016658

 Visit ID
 : SCHIOPV23778

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : SDGfdg Collected : 09/Dec/2023 10:18AM

Received : 09/Dec/2023 11:00AM

Reported : 09/Dec/2023 03:01PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - TMT - PAN INDIA - FY2324 Test Name Result Unit Bio. Ref. Range Method

HAEMOGLOBIN	15.9	g/dL	13-17	CYANIDE FREE COLOUROMETER
PCV	49.80	%	40-50	PULSE HEIGHT AVERAGE
RBC COUNT	5.29	Million/cu.mm	4.5-5.5	Electrical Impedence
MCV	94.1	fL	83-101	Calculated
MCH	30	pg	27-32	Calculated
MCHC	31.9	g/dL	31.5-34.5	Calculated
R.D.W	12.7	%	11.6-14	Calculated
TOTAL LEUCOCYTE COUNT (TLC)	6,160	cells/cu.mm	4000-10000	Electrical Impedance
DIFFERENTIAL LEUCOCYTIC COUNT	(DLC)			·
NEUTROPHILS	56.5	%	40-80	Electrical Impedance
LYMPHOCYTES	34.2	%	20-40	Electrical Impedance
EOSINOPHILS	1.4	%	1-6	Electrical Impedance
MONOCYTES	7.4	%	2-10	Electrical Impedance
BASOPHILS	0.5	%	<1-2	Electrical Impedance
ABSOLUTE LEUCOCYTE COUNT				
NEUTROPHILS	3480.4	Cells/cu.mm	2000-7000	Calculated
LYMPHOCYTES	2106.72	Cells/cu.mm	1000-3000	Calculated
EOSINOPHILS	86.24	Cells/cu.mm	20-500	Calculated
MONOCYTES	455.84	Cells/cu.mm	200-1000	Calculated
BASOPHILS	30.8	Cells/cu.mm	0-100	Calculated
PLATELET COUNT	150000	cells/cu.mm	150000-410000	IMPEDENCE/MICROSCOP
ERYTHROCYTE SEDIMENTATION RATE (ESR)	08	mm at the end of 1 hour	0-15	Modified Westergren
PERIPHERAL SMEAR				

RBCs ARE NORMOCYTIC NORMOCHROMIC.

TLC, DLC WITHIN NORMAL LIMIT. NO IMMATURE CELLS ARE SEEN.

PLATELETS ARE ADEQUATE.

NO HEMOPARASITES SEEN

Page 2 of 12





Age/Gender : 29 Y 7 M 19 D/M
UHID/MR No : SCHI.0000016658

Visit ID : SCHIOPV23778

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : SDGfdg Collected : 09/Dec/2023 10:18AM Received : 09/Dec/2023 11:00AM

Reported : 09/Dec/2023 03:01PM Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY					
ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - TMT - PAN INDIA - FY2324					
Test Name Result Unit Bio. Ref. Range Method					

BLOOD GROUP ABO AND RH FACTOR, WHOLE BLOOD EDTA				
BLOOD GROUP TYPE	В		Forward & Reverse Grouping with Slide/Tube Aggluti	
Rh TYPE	NEGATIVE		Forward & Reverse Grouping with Slide/Tube Agglutination	

Page 3 of 12







Age/Gender : 29 Y 7 M 19 D/M
UHID/MR No : SCHI.0000016658

Visit ID : SCHIOPV23778

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : SDGfdg Collected : 09/Dec/2023 10:18AM

Received : 09/Dec/2023 01:27PM Reported : 09/Dec/2023 02:35PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - TMT - PAN INDIA - FY2324					
Test Name	Result	Unit	Bio. Ref. Range	Method	

Comment:

As per American Diabetes Guidelines, 2023

is per rimerican Diabetes Guidelines, 2020			
Fasting Glucose Values in mg/dL	Interpretation		
70-100 mg/dL	Normal		
100-125 mg/dL	Prediabetes		
≥126 mg/dL	Diabetes		
<70 mg/dL	Hypoglycemia		

Note:

- 1. The diagnosis of Diabetes requires a fasting plasma glucose of > or = 126 mg/dL and/or a random / 2 hr post glucose value of > or = 200 mg/dL on at least 2 occasions.
- 2. Very high glucose levels (>450 mg/dL in adults) may result in Diabetic Ketoacidosis & is considered critical.

GLUCOSE, POST PRANDIAL (PP), 2	90	mg/dL	70-140	GOD - POD
HOURS , SODIUM FLUORIDE PLASMA (2				
HR)				

Comment:

It is recommended that FBS and PPBS should be interpreted with respect to their Biological reference ranges and not with each other.

Conditions which may lead to lower postprandial glucose levels as compared to fasting glucose levels may be due to reactive hypoglycemia, dietary meal content, duration or timing of sampling after food digestion and absorption, medications such as insulin preparations, sulfonylureas, amylin analogues, or conditions such as overproduction of insulin.

HBA1C, GLYCATED HEMOGLOBIN,	5.5	%	HPLC
WHOLE BLOOD EDTA			
ESTIMATED AVERAGE GLUCOSE (eAG),	111	mg/dL	Calculated
WHOLE BLOOD EDTA		-	

Comment:

Reference Range as per American Diabetes Association (ADA) 2023 Guidelines:

REFERENCE GROUP	HBA1C %
NON DIABETIC	<5.7
PREDIABETES	5.7 – 6.4

Page 4 of 12





Age/Gender : 29 Y 7 M 19 D/M
UHID/MR No : SCHI.0000016658

Visit ID : SCHIOPV23778

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : SDGfdg Collected : 09/Dec/2023 10:18AM

Received : 09/Dec/2023 01:27PM Reported : 09/Dec/2023 02:35PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - TMT - PAN INDIA - FY2324					
Test Name	Result	Unit	Bio. Ref. Range	Method	

DIABETES	≥ 6.5
DIABETICS	
EXCELLENT CONTROL	6 – 7
FAIR TO GOOD CONTROL	7 – 8
UNSATISFACTORY CONTROL	8 – 10
POOR CONTROL	>10

Note: Dietary preparation or fasting is not required.

1. HbA1C is recommended by American Diabetes Association for Diagnosing Diabetes and monitoring Glycemic

Control by American Diabetes Association guidelines 2023.

- 2. Trends in HbA1C values is a better indicator of Glycemic control than a single test.
- 3. Low HbA1C in Non-Diabetic patients are associated with Anemia (Iron Deficiency/Hemolytic), Liver Disorders, Chronic Kidney Disease. Clinical Correlation is advised in interpretation of low Values.
- 4. Falsely low HbA1c (below 4%) may be observed in patients with clinical conditions that shorten erythrocyte life span or decrease mean erythrocyte age. HbA1c may not accurately reflect glycemic control when clinical conditions that affect erythrocyte survival are present.
- 5. In cases of Interference of Hemoglobin variants in HbA1C, alternative methods (Fructosamine) estimation is recommended for Glycemic Control
 - A: HbF >25%
 - B: Homozygous Hemoglobinopathy.
 - (Hb Electrophoresis is recommended method for detection of Hemoglobinopathy)







Age/Gender : 29 Y 7 M 19 D/M UHID/MR No : SCHI.0000016658

Visit ID : SCHIOPV23778

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : SDGfdg Collected : 09/Dec/2023 10:18AM

Received : 09/Dec/2023 04:11PM Reported : 09/Dec/2023 06:09PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - TMT - PAN INDIA - FY2324					
Test Name	Result	Unit	Bio. Ref. Range	Method	

LIPID PROFILE, SERUM				
TOTAL CHOLESTEROL	185	mg/dL	<200	CHE/CHO/POD
TRIGLYCERIDES	70	mg/dL	<150	Enzymatic
HDL CHOLESTEROL	49	mg/dL	>40	CHE/CHO/POD
NON-HDL CHOLESTEROL	136	mg/dL	<130	Calculated
LDL CHOLESTEROL	121.92	mg/dL	<100	Calculated
VLDL CHOLESTEROL	13.98	mg/dL	<30	Calculated
CHOL / HDL RATIO	3.75		0-4.97	Calculated

Comment:

Reference Interval as per National Cholesterol Education Program (NCEP) Adult Treatment Panel III Report.

	Desirable	Borderline High	High	Very High
TOTAL CHOLESTEROL	< 200	200 - 239	≥ 240	
TRIGLYCERIDES	<150	150 - 199	200 - 499	≥ 500
III .I D1 .	Optimal < 100 Near Optimal 100-129	130 - 159	160 - 189	≥ 190
HDL	≥ 60			
INON-HDL CHOLESTEROL	Optimal <130; Above Optimal 130-159	160-189	190-219	>220

- 1. Measurements in the same patient on different days can show physiological and analytical variations.
- 2. NCEP ATP III identifies non-HDL cholesterol as a secondary target of therapy in persons with high triglycerides.
- 3. Primary prevention algorithm now includes absolute risk estimation and lower LDL Cholesterol target levels to determine eligibility of drug therapy.
- **4.** Low HDL levels are associated with Coronary Heart Disease due to insufficient HDL being available to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues.
- **5.** As per NCEP guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.
- **6.** VLDL, LDL Cholesterol Non HDL Cholesterol, CHOL/HDL RATIO, LDL/HDL RATIO are calculated parameters when Triglycerides are below 350mg/dl. When Triglycerides are more than 350 mg/dl LDL cholesterol is a direct measurement.

Page 6 of 12









Age/Gender : 29 Y 7 M 19 D/M
UHID/MR No : SCHI.0000016658

Visit ID : SCHIOPV23778

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : SDGfdg Collected : 09/Dec/2023 10:18AM Received : 09/Dec/2023 04:11PM

Reported : 09/Dec/2023 06:09PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - TMT - PAN INDIA - FY2324				
Test Name	Result	Unit	Bio. Ref. Range	Method

LIVER FUNCTION TEST (LFT), SERUM				
BILIRUBIN, TOTAL	0.67	mg/dL	0.20-1.20	Colorimetric
BILIRUBIN CONJUGATED (DIRECT)	0.13	mg/dL	0.0-0.3	Calculated
BILIRUBIN (INDIRECT)	0.54	mg/dL	0.0-1.1	Dual Wavelength
ALANINE AMINOTRANSFERASE (ALT/SGPT)	83.6	U/L	21-72	UV with P-5-P
ASPARTATE AMINOTRANSFERASE (AST/SGOT)	42.8	U/L	17-59	UV with P-5-P
ALKALINE PHOSPHATASE	87.00	U/L	38-126	p-nitrophenyl phosphate
PROTEIN, TOTAL	6.81	g/dL	6.3-8.2	Biuret
ALBUMIN	4.59	g/dL	3.5 - 5	Bromocresol Green
GLOBULIN	2.22	g/dL	2.0-3.5	Calculated
A/G RATIO	2.07		0.9-2.0	Calculated

Comment:

 $LFT\ results\ reflect\ different\ aspects\ of\ the\ health\ of\ the\ liver,\ i.e.,\ hepatocyte\ integrity\ (AST\ \&\ ALT),\ synthesis\ and\ secretion\ of\ bile\ (Bilirubin,\ ALP),\ cholestasis\ (ALP,\ GGT),\ protein\ synthesis\ (Albumin)$

Common patterns seen:

1. Hepatocellular Injury:

- AST Elevated levels can be seen. However, it is not specific to liver and can be raised in cardiac and skeletal injuries.
- ALT Elevated levels indicate hepatocellular damage. It is considered to be most specific lab test for hepatocellular injury. Values also correlate well with increasing BMI.
- Disproportionate increase in AST, ALT compared with ALP.
- Bilirubin may be elevated.
- AST: ALT (ratio) In case of hepatocellular injury AST: ALT > 1In Alcoholic Liver Disease AST: ALT usually >2. This ratio is also seen to be increased in NAFLD, Wilsons's diseases, Cirrhosis, but the increase is usually not >2.

2. Cholestatic Pattern:

- \bullet ALP Disproportionate increase in ALP compared with AST, ALT.
- · Bilirubin may be elevated.
- ALP elevation also seen in pregnancy, impacted by age and sex.
- $\bullet \ To \ establish \ the \ hepatic \ origin \ correlation \ with \ GGT \ helps. \ If \ GGT \ elevated \ indicates \ hepatic \ cause \ of \ increased \ ALP.$

3. Synthetic function impairment:

- Albumin- Liver disease reduces albumin levels.
- Correlation with PT (Prothrombin Time) helps.

Page 7 of 12









Age/Gender : 29 Y 7 M 19 D/M
UHID/MR No : SCHI.0000016658

Visit ID : SCHIOPV23778

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : SDGfdg Collected : 09/Dec/2023 10:18AM Received : 09/Dec/2023 04:11PM

Reported : 09/Dec/2023 05:18PM Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY				
ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - TMT - PAN INDIA - FY2324				
Test Name Result Unit Bio. Ref. Range Method				

RENAL PROFILE/KIDNEY FUNCTION TEST (RFT/KFT), SERUM				
CREATININE	0.88	mg/dL	0.66-1.25	Creatinine amidohydrolase
UREA	23.40	mg/dL	19-43	Urease
BLOOD UREA NITROGEN	10.9	mg/dL	8.0 - 23.0	Calculated
URIC ACID	6.32	mg/dL	3.5-8.5	Uricase
CALCIUM	9.60	mg/dL	8.4 - 10.2	Arsenazo-III
PHOSPHORUS, INORGANIC	4.06	mg/dL	2.5-4.5	PMA Phenol
SODIUM	135.9	mmol/L	135-145	Direct ISE
POTASSIUM	4.7	mmol/L	3.5-5.1	Direct ISE
CHLORIDE	102.3	mmol/L	98 - 107	Direct ISE

Page 8 of 12







Age/Gender : 29 Y 7 M 19 D/M
UHID/MR No : SCHI.0000016658
Visit ID : SCHIOPV23778

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : SDGfdg Collected : 09/Dec/2023 10:18AM Received : 09/Dec/2023 04:11PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

: 09/Dec/2023 05:18PM

DEPARTMENT OF BIOCHEMISTRY			
ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - TMT - PAN INDIA - FY2324			
Test Name Result Unit Bio. Ref. Range Method			

Reported

GAMMA GLUTAMYL TRANSPEPTIDASE	48.20	U/L	15-73	Glyclyclycine
(GGT) , SERUM				Nitoranalide

Page 9 of 12







Age/Gender : 29 Y 7 M 19 D/M
UHID/MR No : SCHI.0000016658

Visit ID : SCHIOPV23778

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : SDGfdg Collected : 09/Dec/2023 10:18AM

Received : 09/Dec/2023 11:00AM Reported : 09/Dec/2023 03:07PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF IMMUNOLOGY

	DELYMENT OF IMMOREGACE				
ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - TMT - PAN INDIA - FY2324					
Test Name	Result	Unit	Bio. Ref. Range	Method	

THYROID PROFILE TOTAL (T3, T4, TSH), SERUM				
TRI-IODOTHYRONINE (T3, TOTAL)	1.71	ng/mL	0.67-1.81	ELFA
THYROXINE (T4, TOTAL)	7.09	μg/dL	4.66-9.32	ELFA
THYROID STIMULATING HORMONE (TSH)	2.780	μIU/mL	0.25-5.0	ELFA

Comment:

lkor nregnant females	Bio Ref Range for TSH in uIU/ml (As per American Thyroid Association)
First trimester	0.1 - 2.5
Second trimester	0.2 - 3.0
Third trimester	0.3 - 3.0

- 1. TSH is a glycoprotein hormone secreted by the anterior pituitary. TSH activates production of T3 (Triiodothyronine) and its prohormone T4 (Thyroxine). Increased blood level of T3 and T4 inhibit production of TSH.
- **2.** TSH is elevated in primary hypothyroidism and will be low in primary hyperthyroidism. Elevated or low TSH in the context of normal free thyroxine is often referred to as sub-clinical hypo- or hyperthyroidism respectively.
- 3. Both T4 & T3 provides limited clinical information as both are highly bound to proteins in circulation and reflects mostly inactive hormone. Only a very small fraction of circulating hormone is free and biologically active.
- 4. Significant variations in TSH can occur with circadian rhythm, hormonal status, stress, sleep deprivation, medication & circulating antibodies.

TSH	Т3	T4	FT4	Conditions
High	Low	Low	Low	Primary Hypothyroidism, Post Thyroidectomy, Chronic Autoimmune Thyroiditis
High	N	N	IN	Subclinical Hypothyroidism, Autoimmune Thyroiditis, Insufficient Hormone Replacement Therapy.
N/Low	Low	Low	Low	Secondary and Tertiary Hypothyroidism
Low	High	High	High	Primary Hyperthyroidism, Goitre, Thyroiditis, Drug effects, Early Pregnancy
Low	N	N	N	Subclinical Hyperthyroidism
Low	Low	Low	Low	Central Hypothyroidism, Treatment with Hyperthyroidism
Low	N	High	High	Thyroiditis, Interfering Antibodies
N/Low	High	N	N	T3 Thyrotoxicosis, Non thyroidal causes
High	High	High	High	Pituitary Adenoma; TSHoma/Thyrotropinoma

Page 10 of 12







Age/Gender : 29 Y 7 M 19 D/M UHID/MR No : SCHI.0000016658

Visit ID : SCHIOPV23778

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : SDGfdg Collected : 09/Dec/2023 10:18AM Received : 09/Dec/2023 12:21PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

: 09/Dec/2023 02:32PM

DEPARTMENT OF CLINICAL PATHOLOGY					
ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - TMT - PAN INDIA - FY2324					
Test Name	Result	Unit	Bio. Ref. Range	Method	

Reported

COMPLETE URINE EXAMINATION (CUE), URINE			
PHYSICAL EXAMINATION				
COLOUR	YELLOW		PALE YELLOW	Visual
TRANSPARENCY	CLEAR		CLEAR	Visual
рН	6.0		5-7.5	Bromothymol Blue
SP. GRAVITY	1.030		1.002-1.030	Dipstick
BIOCHEMICAL EXAMINATION			•	
URINE PROTEIN	NEGATIVE		NEGATIVE	PROTEIN ERROR OF INDICATOR
GLUCOSE	NEGATIVE		NEGATIVE	GOD-POD
URINE BILIRUBIN	NEGATIVE		NEGATIVE	AZO COUPLING
URINE KETONES (RANDOM)	NEGATIVE		NEGATIVE	NITROPRUSSIDE
UROBILINOGEN	NORMAL		NORMAL	EHRLICH
BLOOD	NEGATIVE		NEGATIVE	Dipstick
NITRITE	NEGATIVE		NEGATIVE	Dipstick
LEUCOCYTE ESTERASE	NEGATIVE		NEGATIVE	PYRROLE HYDROLYSIS
CENTRIFUGED SEDIMENT WET MOUI	NT AND MICROSCOPY	•		
PUS CELLS	1-2	/hpf	0-5	Microscopy
EPITHELIAL CELLS	0-2	/hpf	<10	MICROSCOPY
RBC	ABSENT	/hpf	0-2	MICROSCOPY
CASTS	ABSENT		0-2 Hyaline Cast	MICROSCOPY
CRYSTALS	ABSENT		ABSENT	MICROSCOPY

Page 11 of 12







Age/Gender : 29 Y 7 M 19 D/M
UHID/MR No : SCHI.0000016658

Visit ID : SCHIOPV23778

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : SDGfdg

Consultant Pathology

Collected : 09/Dec/2023 10:18AM

Received : 09/Dec/2023 12:21PM Reported : 09/Dec/2023 02:32PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

ARCOFEMI - MEDIWHEEL	- FULL BODY ANNU	JAL PLUS MALI	E - TMT - PAN INDIA - F	Y2324
Test Name	Result	Unit	Bio. Ref. Range	Method

URINE GLUCOSE(POST PRANDIAL)	NEGATIVE	NEGATIVE	Dipstick	
URINE GLUCOSE(FASTING)	NEGATIVE	NEGATIVE	Dipstick	

*** End Of Report ***

Dr. Tanish Mandal
Dr. SHWETA GUPTA
MBBS,MD (Pathology)
Consultant Pathologist

Dr Nidhi Sachdev M.B.B.S,MD(Pathology) Consultant Pathologist

Page 12 of 12

